Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genor Biopharma Holdings Limited ( (HK:6998) ) has issued an update.
Edding Genor Group Holdings Limited announced that its innovative small nucleic acid drug EDP167 has completed first subject dosing in a Phase II clinical trial for adult patients with homozygous familial hypercholesterolemia. The multicenter, dose-finding, open-label study will assess changes in LDL cholesterol after 24 weeks, with primary endpoint data expected in the fourth quarter of 2026.
EDP167 is an siRNA therapeutic targeting hepatic ANGPTL3, enabling dual reductions in LDL cholesterol and triglycerides through a mechanism independent of the LDL receptor pathway and potentially addressing the limitations of statins and PCSK9 inhibitors. Earlier Phase I data in healthy volunteers and patients with mild dyslipidemia showed a favorable safety and tolerability profile, positioning EDP167 as a promising future treatment option for severe and mixed dyslipidemia and reinforcing the company’s strategic push into cardiovascular medicine.
The most recent analyst rating on (HK:6998) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Genor Biopharma Holdings Limited stock, see the HK:6998 Stock Forecast page.
More about Genor Biopharma Holdings Limited
Edding Genor Group Holdings Limited is an integrated specialty biopharmaceutical company focused on oncology, autoimmune, cardiovascular and respiratory diseases, as well as anti-infectives. By acquiring branded drug assets from multinational pharmaceutical companies and licensing innovative patented drugs, it has built a portfolio of originator-branded and novel therapies and successfully launched multiple innovative drugs in China, supported by strong clinical development and high-quality manufacturing capabilities.
YTD Price Performance: -5.00%
Average Trading Volume: 1,244,375
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.72B
See more insights into 6998 stock on TipRanks’ Stock Analysis page.